NCDR: Oral Anticoagulation: Failures at Both Ends of AF Risk Spectrum

(3:52)

Post-procedural Anticoagulation Strategies after WATCHMAN or LAAO featuring Dr. Joe Walsh

(25:57)

NCDR: Intro of NOACs Has Improved Overall Anticoagulation Rates

(7:1econd)

AHA 2015 | Findings From the NCDR-CathPCI Registry

(4:34)

Canadian Perspectives on the ACC 2023 - Oral PCSK9i Trial

(4:27)

Acute coronary syndromes \u0026 acute myocardial infarction

(21:52)

NOAC for Atrial fibrilliation Management - We Already Have the Best Option in the Market

(36:31)

ACC.11 | NCDR Research Presentation

(4:42)

ACC.11 | NCDR Research Presentation

(4:42)

M LAA closure for Atrial Fibrillation Management - Its time to take the leap

(26:13)

The Role of the Nurse in nmCRPC Patient Management

(5:29)

The latest in implantable cardioverter defibrillator therapy

(52:1econd)

Chronic Kidney Disease: Best Practices for Screening Patients in the Cath Lab

(57:20)

How Renal Function and Comorbidities Affect Dosing for NOACs

(1:12)

Comparative Effectiveness of LAAO Among AFib Patients Undergoing Cardiac Surgery

(3:32)

Radcliffe Cardiology - NOAC RTD - Session 4

(15:39)

First Experience With Amulet in the United States | JACC: Cardiovascular Interventions

(10:31)

NOAC- ORAL ANTICOAGULANTS

(1:2:32)